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Despite evidence that preoperative aspirin improves outcomes in cardiac surgery, recom-
mendations for aspirin use are inconsistent due to aspirin’s anti-platelet effect and concern
for bleeding. The purpose of this study was to investigate preoperative aspirin use and its
effect on bleeding and transfusion in cardiac surgery.
Methods
This retrospective study involved consecutive patients (n=1571) who underwent CABG,
valve, or combined CABG and valve surgery at a single center between March 2007 and
July 2012. Of all patients, 728 met the inclusion criteria and were divided into two groups:
those using (n=603) or not using (n=125) aspirin within 5 days of surgery. Data were col-
lected on chest tube drainage, re-operation for bleeding, and transfusion of red blood cells
(RBCs), fresh frozen plasma (FFP), and platelets.
Results
No significant difference was observed between the two groups in chest tube drainage or re-
operation for bleeding. An increase in patients transfused with RBCs was observed in the
aspirin group (61.9 vs 51.2%, adjusted OR 1.77, p=0.027); however, among those trans-
fused RBCs, no significant difference in mean units transfused or massive transfusion was
observed. No significant difference was seen in transfusion requirement of FFP or platelets.
Conclusions
In patients undergoing CABG, valve, or combined CABG/valve surgery, preoperative aspi-
rin, within 5 days of surgery, was associated with an increased probability of receiving an
PLOSONE | DOI:10.1371/journal.pone.0134670 July 31, 2015 1 / 10
OPEN ACCESS
Citation: Goldhammer JE, Marhefka GD, Daskalakis
C, Berguson MW, Bowen JE, Diehl JT, et al. (2015)
The Effect of Aspirin on Bleeding and Transfusion in
Contemporary Cardiac Surgery. PLoS ONE 10(7):
e0134670. doi:10.1371/journal.pone.0134670
Editor: Giacomo Frati, Sapienza University of Rome,
ITALY
Received: April 30, 2015
Accepted: July 13, 2015
Published: July 31, 2015
Copyright: © 2015 Goldhammer et al. This is an
open access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available from
the Thomas Jefferson University Institutional Cardiac
Surgery Database for researchers who meet the
criteria for access to confidential data as managed by
Thomas Jefferson University Institutional Review
Board. Data is not publicly available due to private
patient information contained within the data set.
Researchers interested in data access may contact
Margaret Lusardi, administrator, Division of Cardiac
Surgery at Thomas Jefferson University Hospital; or
Jordan Goldhammer, Department of Anesthesiology
at Thomas Jefferson University Hospital.
RBC transfusion. Preoperative aspirin was not associated with an increase in chest tube
drainage, re-operation for bleeding complications, or transfusion of FFP or platelets.
Introduction
Aspirin is used universally as an analgesic, anti-pyretic, anti-inflammatory, and anti-platelet
agent. The use of aspirin to prevent cardiovascular complications in patients at risk for acute
coronary syndrome and cerebrovascular events is well documented. In coronary artery bypass
grafting (CABG), early postoperative aspirin therapy is associated with superior in-hospital
and long-term outcomes attributed to improved graft patency [1–4], and postoperative aspirin
use, within 48 hours of CABG surgery, is now the standard of care. Additionally, there is a
growing amount of clinical data to suggest that preoperative aspirin may improve postopera-
tive outcomes in cardiac surgery patients. Several retrospective cohort studies have identified a
significant decrease of in-hospital mortality when patients are treated with preoperative aspirin
[5–7]. However, despite contemporary evidence that preoperative aspirin improves postopera-
tive outcome in cardiac surgery, the recommendations for preoperative aspirin use are incon-
sistent [8–10].
The overwhelming concern regarding perioperative aspirin is increased bleeding and its
associated complications. A series of five randomized controlled trials from 1988 through 1994
showed an increase in transfusion, re-exploration, and chest tube drainage in patients treated
with preoperative aspirin [11–15]. Observational studies have published both positive and neg-
ative associations between aspirin, transfusion, and bleeding [4–6, 16, 17]; however, it is diffi-
cult to draw conclusions from the existing body of literature due to the lack of contemporary
studies utilizing blood conservation techniques. Thus, this study was designed to investigate
transfusion and bleeding complications secondary to preoperative aspirin in a contemporary
cardiac surgery population. We investigated bleeding and transfusion in patients undergoing
CABG, valve, or combined CABG/valve surgery, and hypothesized that no significant increase
in transfusion or bleeding complications would be observed in the aspirin treated population
due to the use of contemporary blood conservation strategies including: cell salvage, anti-fibri-
nolytic medications, and conservative blood product transfusion.
Materials and Methods
Study Design
This study was in compliance with the Declaration of Helsinki and reviewed and approved by
the Thomas Jefferson University Institutional Review Board. Written informed consent was
waived by the IRB and data was de-identified prior to analysis. This retrospective cohort study
involved consecutive patients (n = 1571) having cardiac surgery including CABG, valve, or
combined CABG and valve surgery at an academic medical center between March 2007 and
July 2012. The patients excluded from the study cohort were those younger than 18, on preop-
erative anticoagulants, glycoprotein IIb/IIIa inhibitors, ADP inhibitors, or with incomplete
documentation of aspirin use. Of all patients, 728 met the inclusion criteria and were divided
into two groups; those using (n = 603) or not using (n = 125) preoperative aspirin (Fig 1). Pre-
operative aspirin use was defined as any dose of aspirin within five days of surgery.
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Data Collection
Data collected included demographics, medical history, and perioperative clinical data. Data
were collected and organized to follow the template of the Society of Thoracic Surgeons data-
base. Demographic and medical history data were collected upon hospital admission for car-
diac surgery. Clinical data were collected in a prospective manner during the hospitalization
for surgery.
Major outcomes of this study were bleeding and transfusion. Intraoperative transfusion
data were collected from the electronic anesthesia record. Postoperative transfusion data were
collected from the electronic medical record as indicated by physician order entry for transfu-
sion of red blood cells (RBCs), fresh frozen plasma (FFP), and platelets. All transfusion data
within five days of surgery were included in the analysis. Chest tube data was collected from
the electronic medical record and followed until chest tube removal or postoperative day #5.
Re-operation for bleeding complications was defined as any need for re-operation indicated by
high chest tube output or cardiac tamponade. All operative notes from the hospital admission
for cardiac surgery were reviewed to indicate if the patient underwent a re-operation due to
bleeding complications.
Statistical Analysis
Continuous variables were summarized with mean and standard deviation or geometric mean
and interquartile range (25th to 75th percentile), depending upon their distribution. The main
continuous outcomes (RBC, FFP, and platelet units; chest tube drainage volume and days)
were log transformed prior to the analyses because of their skewed distribution. Univariable
(unadjusted) analyses were based on t-tests for the continuous variables and chi-square tests
Fig 1. Study Inclusion/Exclusion Criteria.
doi:10.1371/journal.pone.0134670.g001
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(or Fisher’s exact tests, in the case of sparse data) for the categorical variables. Multivariable
analyses were used to control for confounding factors between the aspirin and non-aspirin
patient population. Demographic characteristics (sex, age, obesity), past medical history (dia-
betes, hypertension, cerebrovascular disease, peripheral vascular disease, chronic lung disease,
renal failure, congestive heart disease, previous myocardial infarction, preoperative hemato-
crit), medications (beta blockers, angiotensin converting enzyme (ACE) or angiotensin recep-
tor blocker (ARB) inhibitor, lipid lowering medications), and surgical characteristics (type of
operation, perfusion time) were controlled for in the final models. Multivariable analyses were
based on linear regression for the continuous outcomes and logistic regression for the dichoto-
mous outcomes. The aspirin effects on the mean units transfused and chest tube drainage were
expressed as geometric mean ratios (GMR), while the aspirin effects on the proportion of
patients needing transfusion or re-exploration were expressed as odds ratios (OR). All reported
P-values were 2-sided, and P< 0.05 was considered to be statistically significant. Statistical
analysis was performed with SPSS 17.0 software for Windows.
Results
Clinical Characteristics
Of the 1571 patients in the database receiving CABG, valve, or combined CABG and valve sur-
gery, 728 met the inclusion criteria and were divided into two groups: Those using (n = 603) or
not using (n = 125) preoperative aspirin. Demographic and clinical data of the two patient groups
are presented in Table 1. Patients treated with preoperative aspirin were more likely to have an
increased age (66 vs 60 years, p =<0.001) and BMI (29.1 vs 27.6 kg/m2, p = 0.009). Additionally,
aspirin users were more likely to have a past medical history of diabetes (35.0% vs 20.8%,
p = 0.002), hypertension (89.6% vs 68.0%, p =<0.001), peripheral vascular disease (11.8% vs
4.8%, p = 0.021), previous myocardial infarction (26.9% vs 11.2%, p =<0.001), and a family his-
tory of coronary artery disease (53.6% vs 31.2%, p =<0.001). Patients on aspirin were more fre-
quently treated with beta blockers (75.8% vs 42.4%, p =<0.001), ACE inhibitors or ARBs (46.4%
vs 27.2%, p =<0.001), and lipid lowering medications (79.4% vs 36.8%, p =<0.001). Aspirin
users and non-users did not differ in preoperative hematocrit (37.9% vs 38.1%, p = 0.606).
Procedure Characteristics
Of the 728 patients in the study population, 54.1% underwent CABG surgery, 32.8% valve sur-
gery, and 13.0% combined CABG and valve surgery. Patients on aspirin were more likely to
have a CABG operation (p =<0.001). Both cross clamp time (76 vs 91 minutes, p = 0.001) and
perfusion time (96 vs 119 minutes, p = 0.001) were decreased in patients on preoperative aspi-
rin. The incidence of previous cardiac surgery was similar between the two groups (6.3% vs
8.0%, p = 0.486), as was the administered dose of ε-aminocaproic acid (9.4 vs 9.4 G, p = 0.956)
and the amount of cell salvage transfused (461 vs 447 ml, p = 0.618).
Transfusion Outcomes
Overall, 60.7% of patients required transfusion of RBCs, 28.3% FFP, and 27.6% platelets. Of the
patients on aspirin therapy, 61.9% required transfusion of RBCs, 27.2% FFP, and 27.4% plate-
lets. A significant increase in the number of patients who received a transfusion of RBCs was
observed in the aspirin population (61.9% vs 55.2%; adjusted OR 1.77; 95% CI 1.07, 2.95;
p = 0.027); however, no significant increase in mean RBC units transfused in those who
required transfusion (2.9 vs 3.1 units, adjusted GMR 1.08, p = 0.494) was observed. As seen in
Table 2, no significant difference was observed in the number of patients receiving transfusion
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or mean units transfused in those who required transfusion of FFP or platelets. No significant
difference was observed in massive transfusion of RBCs (1–4 vs>4 units, adjusted OR 1.00,
p = 0.993), FFP (1–4 vs>4 units, adjusted OR 1.72, p = 0.264), or platelets (1–10 vs>10 units,
adjusted OR 1.14, p = 0.794).
Indicators of Bleeding
Other indicators of bleeding studied were chest tube drainage and re-exploration rate
(Table 3). Patients taking preoperative aspirin had no increase in days of chest tube drainage
(2.6 vs 2.6 days; adjusted GMR 1.03; p = 0.444) or volume of chest tube drainage (874 vs 712
ml; adjusted GMR 1.16, p = 0.065). Additionally, no difference was observed in re-operation
for bleeding complications. Patients on aspirin required re-operation for bleeding at a rate of
4.1%, non-aspirin users had a re-operation incidence of 4.8% (p = 0.742).
Table 1. Demographic and Clinical Characteristics.
Characteristics Aspirin P value
Yes No
N = 603 N = 125
Age (yrs) 66±11 60±15 <0.001
Male gender 402(66.7) 76(60.8) 0.209
Body mass index (kg/m2) 29.1±5.9 27.6±6.2 0.009
Past medical history
Diabetes 211(35.0) 26(20.8) 0.002
Hypertension 540(89.6) 85(68.0) <0.001
Smoker 112(18.6) 21(16.8) 0.640
Cerebrovascular disease 86(14.3) 10(8.0) 0.060
Peripheral vascular disease 71(11.8) 6(4.8) 0.021
Chronic lung disease 120(19.9) 20(16.0) 0.314
Renal failure 29(4.8) 5(4.0) 0.696
Family history CAD 323(53.6) 39(31.2) <0.001
Congestive heart failure 86(14.3) 19(15.2) 0.786
Previous MI 162(26.9) 14(11.2) <0.001
Preoperative Hematocrit (%) 37.9±5.2 38.1±5.4 0.606
Medical therapy
Beta-blockers 457(75.8) 53(42.4) <0.001
ACE inhibitors or ARB 280(46.4) 34(27.2) <0.001
Lipid lowering agent 479(79.4) 46(36.8) <0.001
Type of Surgery
CABG 372(61.7) 22(17.6)
Valve Replacement 152(25.2) 87(69.6)
CABG + Valve 79(13.1) 16(12.8) <0.001
Operative Characteristics
Previous cardiac surgery 38(6.3) 10(8.0) 0.486
ε-Aminocaproic acid (G) 9.4±3.9 9.4±3.1 0.956
Cell Saver (ml) 461±281 447±301 0.618
Perfusion time (min) 96±47 119±56 <0.001
Cross-clamp time (min) 76±29 91±39 <0.001
Values are n (%) for categorical variables and mean±SD for continuous variables.
doi:10.1371/journal.pone.0134670.t001
Aspirin, Bleeding and Transfusion in Cardiac Surgery
PLOS ONE | DOI:10.1371/journal.pone.0134670 July 31, 2015 5 / 10
Discussion
Recent studies have shown the benefit of preoperative aspirin at reducing cardiac, cerebral, and
renal complications, as well as in-hospital mortality for cardiac surgery patients. Cao et al,
investigating a diverse patient population undergoing CABG, valve, or combined CABG and
Table 2. Transfusion Outcomes, Aspirin vs No Aspirin.
Blood Product Aspirin Unadjusted P value Adjusted 95% CI P value
Yes No OR1 or GMR2 OR1 or GMR2
N = 603 N = 125
Red Blood Cells
Patients Transfused 373(61.9) 69(55.2) 1.321 0.165 1.771 1.07, 2.95 0.027
Number of Units*
1–4 283(75.9) 47(68.1)
>4 90(24.1) 22(31.9) 0.681 0.174 1.001 0.49, 2.03 0.993
Mean Units* 2.9 [2,4] 3.1 [2,6] 0.942 0.581 1.082 0.87, 1.35 0.494
Fresh Frozen Plasma
Patients Transfused 164(27.2) 42(33.6) 0.741 0.148 1.211 0.72, 2.04 0.461
Number of Units*
1–4 108(65.9) 29(69.0)
>4 56(34.1) 13(31.0) 1.161 0.696 1.721 0.66, 4.48 0.264
Mean Units* 3.9 [2,6] 4.0 [2,6] 0.992 0.967 1.092 0.80, 1.50 0.580
Platelets
Patients Transfused 165(27.4) 36(28.8) 0.931 0.744 1.191 0.70, 2.03 0.529
Number of Units*
1–10 115(69.7) 21(58.3)
>10 50(30.3) 15(41.7) 0.611 0.187 1.141 0.42, 3.10 0.794
Mean Units* 10.5 [8, 15] 12.2 [10, 20] 0.862 0.201 1.022 0.77, 1.34 0.900
Values are n (%) or categorical variables and geometric mean, IQR [25, 75] for continuous variables.
P <0.05 considered signiﬁcant.
* Among patients transfused.
1Odds Ratio (OR).
2Geometric Mean Ratio (GMR).
doi:10.1371/journal.pone.0134670.t002
Table 3. Postoperative Bleeding, Aspirin vs No Aspirin.
Bleeding Outcome Aspirin Unadjusted P value Adjusted 95% CI P value
Yes No OR1 or GMR2 OR1 or GMR2
N = 603 N = 125
Re-exploration 25(4.1) 6(4.8) 0.861 0.742
Chest Tube Drainage
Volume (ml) 874 [553,1311] 712 [417,1152] 1.232 0.004 1.162 0.99, 1.35 0.065
Days 2.6 [2,3] 2.6 [2,3] 1.022 0.532 1.032 0.95, 1.12 0.444
Values are n (%) for categorical variables and geometric mean, IQR [25, 75] for continuous variables.
P <0.05 considered signiﬁcant.
1Odds Ratio (OR).
2Geometric Mean Ratio (GMR).
doi:10.1371/journal.pone.0134670.t003
Aspirin, Bleeding and Transfusion in Cardiac Surgery
PLOS ONE | DOI:10.1371/journal.pone.0134670 July 31, 2015 6 / 10
valve surgery, demonstrated preoperative aspirin to be associated with a significant decline in
30-day mortality, renal failure, and adverse cardiocerebral events, including; stroke, coma,
heart block, and perioperative myocardial ischemia [7]. However, current practice guidelines
remain conservative in their endorsement of preoperative aspirin. The 2011 American College
of Cardiology/American Heart Association Guidelines for Coronary Artery Bypass Surgery,
citing recent evidence that preoperative aspirin decreases morbidity and mortality, offers a
class I recommendation to administer aspirin prior to CABG surgery; however, no specific rec-
ommendations of dose or discontinuation time are offered [8]. Conversely, the Society of Tho-
racic Surgeons 2005 guidelines suggest discontinuing aspirin therapy 3–5 days before elective
CABG in order to decrease transfusion related complications [9]. A 2012 update to these guide-
lines maintains a recommendation to discontinue aspirin before elective surgery and in those
at high risk for bleeding [10]. Despite contemporary evidence for improved perioperative out-
come, the major guidelines offer conflicting recommendations for preoperative aspirin.
The existing literature exploring bleeding and transfusion due to aspirin must be applied
with caution to contemporary cardiac surgery for a number of reasons. First, it has been more
than twenty years since the often cited, randomized, controlled trials of aspirin’s effect on
bleeding and transfusion [11–15]. Over the last two decades the universal use of cell salvage
methods and anti-fibrinolytic medications have helped to decrease blood loss and transfusion
in cardiac surgery [18,19]. Additionally, many institutions now utilize restrictive transfusion
due to increased awareness of infection, immunosuppression, and transfusion reaction second-
ary to blood product administration. For these reasons, an updated look at the bleeding com-
plications of aspirin is warranted using both conservative transfusion strategies and modern
cell salvage techniques.
The major transfusion related finding of this observational cohort study is that preoperative
aspirin is associated with an increased incidence of blood product administration. Aspirin
users and non-users had a similar baseline hematocrit; however, after adjustment for con-
founding factors, aspirin was associated with a 77% relative increase in the incidence of red
blood cell transfusion. An increase in transfusion of fresh frozen plasma was detected; however,
this minor trend did not reach statistical significance. Interestingly, we did not detect a signifi-
cant increase in platelet transfusion. This may be related to the relative scarcity of point of care
testing regarding qualitative platelet function, and the reliance on quantitative platelet assess-
ment (i.e. platelet count), which remains largely unaffected by aspirin therapy. In contrast,
intraoperative hemoglobin and hematocrit levels may be expeditiously obtained, interpreted,
and acted upon; perhaps accounting for increased red blood cell transfusion in patients exhibit-
ing bleeding and anemia secondary to platelet inhibition.
Complications of blood transfusion are rare, but can be life threatening. Most reported
transfusion reactions occur secondary to administration of mismatched blood products, a com-
plication that can be avoided with vigilance. The incidence of serious transfusion related com-
plications occurs approximately 1/1,100 transfusions and may occur more frequently in a
massive transfusion setting [20]. Aspirin exposed patients in our cohort displayed no increase
in massive transfusion of RBCs, FFP, or platelets; potentially mitigating some transfusion
related risk of mismatched product administration, volume overload, and infectious complica-
tions. Overall, the potential benefits of preoperative aspirin must be weighed against the associ-
ated clinical risk of blood product administration.
Surgical re-exploration is associated with significant postoperative mortality and prolonged
hospital stay [21,22]. The overall re-exploration rate in this surgical cohort was 4.2%, well within
the historical range of 2% to 6%. Preoperative aspirin was not associated with an increase in re-
exploration or chest tube output within our study group. Given the rarity of re-operation and
our relatively small sample size, we were unable to adjust the incidence of re-exploration using
Aspirin, Bleeding and Transfusion in Cardiac Surgery
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regression analysis; however, it can safely be concluded from our unadjusted data that there is
not an overwhelming signal linking aspirin to immediate re-operation for bleeding.
Previous literature has shown that the beneficial effects of aspirin are not limited to CABG
and are applicable to most cardiac surgery procedures [7, 23–25]; however, the current literature
assessing transfusion and bleeding complications related to preoperative aspirin consist only of
CABG patients. Our study is the first to include valve and combined CABG/valve procedures to
assess the bleeding complications of aspirin. The major guidelines for valve surgery, The Guide-
lines onManagement of Valvular Heart Disease, focus extensively on postoperative anticoagula-
tion and anti-thrombotic treatment and, in fact, completely fail to address the use of aspirin in
the preoperative period [26]. As the applications of preoperative aspirin continue to expand, sub-
group analysis of this population is warranted to further investigate the bleeding risk and mortal-
ity effect of aspirin in patients undergoing isolated valve or combined CABG/valve surgery.
Limitations
Limitations of this study are a direct result of its observational design. Aspirin users differed
from non-aspirin users in demographics, medical history, and surgical characteristics. We have
attempted to account for the differences between the groups with regression analysis; however,
residual confounding cannot be excluded from the results. Randomized, controlled trials of
preoperative aspirin or a larger population to allow for propensity matched, retrospective anal-
ysis would be helpful to eliminate underlying confounding variables.
This study was designed to detect major differences in bleeding, transfusion, and re-explora-
tion between aspirin users and non-users. We observed an increased incidence of RBC transfu-
sion and no significant increase in transfusion of FFP and platelets; however, it must be noted
that we encountered large confidence intervals in our incidence of transfusion analysis. While
we can safely conclude no large effect was observed in transfusion of FFP and platelets, it is
possible aspirin has a more modest effect undetected in this study. Future studies, encompass-
ing large patient cohorts, will help to define the transfusion related risk of aspirin.
Our clinicians practice restrictive transfusion medicine and the decision to initiate blood
product transfusion in our cohort was based upon clinical experience; however, a more accu-
rate assessment of transfusion may have been possible with a lab based transfusion protocol.
Overall, 60.7% of patients received an RBC transfusion within five days of surgery. While this
transfusion rate seems elevated, it should be noted that our incidence of transfusion analysis
includes blood products administered through postoperative day five, a longer transfusion
interval than previously queried. Historical studies, utilizing restrictive transfusion practices,
have demonstrated an RBC transfusion incidence of 32% within 24 hours of surgery and up to
56% in the first three postoperative days, a transfusion rate which is consistent with our data
[17,27].
An additional limitation of this study is a lack of information regarding aspirin dose. Aspi-
rin use was recorded in a categorical (“yes” or “no”) manner. Precise aspirin dose information
would have been beneficial in order investigate the effects of escalating dose on bleeding and
transfusion.
Conclusions
Our study adds to growing amount of observational data that preoperative aspirin is associated
with increased incidence of RBC transfusion but not associated with increase in re-operation
rate or bleeding complications in cardiac surgery [16]. Multiple recent studies suggest favorable
outcomes in patients treated with aspirin throughout the perioperative period for cardiac sur-
gery [6,7, 23–25]. The risk associated with increased transfusion must be balanced with the risk
Aspirin, Bleeding and Transfusion in Cardiac Surgery
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of ischemic complications from perioperative aspirin interruption. Our results confirm a predi-
lection for increased incidence of RBC transfusion in aspirin treated patients; however, most
importantly, no increase was observed in the side effects that confer the greatest morbidity—
massive transfusion or re-operation for bleeding complications. Although major guidelines still
recommend otherwise, the growing pool of observational data appears to favor aspirin use
throughout the perioperative period for cardiac surgery, with an acceptable accompanied risk
of increased RBC transfusion.
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